AtaiBeckley (ATAI) EBITDA (2020 - 2026)
AtaiBeckley (ATAI) posted quarterly EBITDA of -$30.9 million for Q1 2026, down 51.7% year-over-year from -$64.0 million in Q1 2025, and down 51.7% quarter-over-quarter from -$20.4 million in Q1 2025.
AtaiBeckley (ATAI) EBITDA (2020 - 2026) Analysis & Trends
AtaiBeckley has reported EBITDA for 6 years, with the latest figure at -$28.4 million in Q3 2025.
- Quarterly EBITDA fell 25.81% year-over-year to -$28.4 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$104.3 million (up 1.54% YoY) and the FY2024 annual result came in at -$102.7 million, up 18.16% from the prior year.
- EBITDA for Q1 2026 stood at -$30.9 million, down from -$20.4 million in the prior quarter.
- The five-year high for EBITDA was -$20.4 million in Q1 2025, with the low at -$30.9 million in Q1 2026.
- A 5-year average of -$30.7 million and a median of -$31.9 million in 2023 frame the typical range for EBITDA.
- The widest YoY moves for EBITDA: up 48.22% in 2021, down 952.69% in 2021.
- Over 5 years, EBITDA stood at -$45.2 million in 2021, then rose by 16.85% to -$37.6 million in 2022, then gained by 10.66% to -$33.6 million in 2023, then rose by 9.82% to -$30.3 million in 2024, then increased by 6.04% to -$28.4 million in 2025.
- According to Business Quant data, EBITDA over the past three periods registered -$28.4 million, -$25.3 million, and -$20.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | AtaiBeckley | 2.69 Bn | 2.69 Bn | - | -28.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.14 Mn |
| Mar 31, 2026 | -30.90 Mn |
| Sep 30, 2025 | -28.44 Mn |
| Jun 30, 2025 | -25.27 Mn |
| Mar 31, 2025 | -20.37 Mn |
| Mar 31, 2025 | -20.37 Mn |
| Dec 31, 2024 | -30.27 Mn |
| Sep 30, 2024 | -22.60 Mn |
| Jun 30, 2024 | -25.73 Mn |
| Mar 31, 2024 | -24.09 Mn |
| Dec 31, 2023 | -33.56 Mn |
| Sep 30, 2023 | -26.83 Mn |
| Jun 30, 2023 | -31.86 Mn |
| Mar 31, 2023 | -33.21 Mn |
| Dec 31, 2022 | -37.57 Mn |
| Sep 30, 2022 | -38.42 Mn |
| Jun 30, 2022 | -35.36 Mn |
| Mar 31, 2022 | -33.44 Mn |
| Dec 31, 2021 | -45.18 Mn |
| Sep 30, 2021 | -33.36 Mn |